Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Incyte Corporation's SEC filings document a Nasdaq-listed biopharmaceutical issuer with common stock trading under INCY and product franchises in hematology, oncology, and inflammation and autoimmunity. Form 8-K reports cover operating results, product sales trends for Jakafi and Opzelura, financial guidance, pipeline updates, and regulatory correspondence affecting drug applications.
Proxy and current-report filings also disclose board and executive changes, officer appointments, equity compensation, shareholder voting matters, executive pay, governance practices, and registered security information. These filings frame Incyte's capital structure, leadership oversight, commercial portfolio, clinical-development programs, and regulatory risks.
Incyte Corporation’s Principal Accounting Officer, Tray Thomas, reported receiving an employee stock option grant under the company’s equity plan. On January 16, 2026, Thomas was awarded options to purchase 2,425 shares of Incyte common stock at an exercise price of $106.21 per share.
According to the filing, these options begin to vest on January 16, 2026 in 37 installments. The first 25% of the grant vests on July 15, 2026, and the remaining options vest monthly over the following three years. All 2,425 derivative securities are held directly by the reporting officer.
Incyte Corporation executive Patrick A. Mayes, EVP & Chief Scientific Officer, reported a grant of 4,218 employee stock options on January 16, 2026. These options have an exercise price of $106.21 per share and give the right to buy Incyte common stock.
Beginning January 16, 2026, the options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remaining portion vesting monthly over the following three years, and they expire on January 15, 2036. After this award, Mayes beneficially owns 4,218 derivative securities directly.
Incyte Corporation EVP Michael James Morrissey, Head of Tech. Operations, reported routine equity compensation activity in company common stock. On January 16, 2026, he received an award of 7,426 restricted stock units (RSUs), which will vest in four equal annual installments of 25% and can be settled one-for-one in common shares. On January 20, 2026, 429 shares were automatically withheld by Incyte at $102.62 per share to cover tax obligations tied to previously granted RSUs. After these transactions, Morrissey beneficially owned 34,250 shares of common stock, including 25,198 shares underlying unvested RSUs and earned performance stock units.
Incyte executive Issa Mohamed Khairie reported two stock transactions. On 01/06/2026, 8,264 shares of common stock were automatically withheld by the issuer at a price of $106.66 to cover tax obligations tied to previously granted restricted stock units. On 01/07/2026, Khairie sold 10,856 shares of Incyte common stock at a price of $109.07 per share in an open market transaction. After these transactions, Khairie directly beneficially owned 66,132 shares of common stock, which includes shares issuable from previously reported RSUs that have not yet vested.
Incyte Corporation executive Steven H. Stein, EVP & Chief Medical Officer, reported selling 15,634 shares of Incyte common stock on January 5, 2026 at a price of $101.7 per share. The transaction was reported as a direct sale on a Form 4 insider filing.
After this sale, Stein beneficially owned 34,203 shares of Incyte common stock. This amount includes shares issuable under previously reported restricted stock units and earned performance shares that have been granted but have not yet vested.
A shareholder has filed a notice of proposed sale of 10,856 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ exchange. The shares have an aggregate market value of $1,184,050.89 based on the filer’s stated market price.
The filing indicates the securities were acquired on 01/06/2026 as restricted stock directly from the issuer, with the same date shown for payment and the nature of payment listed as not applicable. The notice also reports that 196,322,703 shares of the issuer’s common stock were outstanding at the time of the filing.
Incyte Corporation’s Executive Vice President and Head of Technical Operations reported several sales of company common stock. On December 16, 2025, the officer sold 833 shares at $97.42 per share and 53,175 shares at $97.29 per share. On December 17, 2025, the officer sold 4,323 shares at $97.26 per share. After these transactions, the officer reported beneficial ownership of 27,507 shares, which the filing explains includes shares issuable under previously reported restricted stock units and earned performance stock units that have not yet vested.
Incyte Corporation reported an insider stock sale by its Executive Vice President and Chief Scientific Officer. On 12/10/2025, the officer sold 5,553 shares of common stock at $95.58 per share. On 12/11/2025, they sold another 255 shares at $94.94 per share. After these transactions, the reporting person directly beneficially owns 60,011 common shares. A footnote also identifies 59,858 additional shares of common stock issuable under previously reported restricted stock units that have not yet vested.
Incyte Corp’s Executive Vice President & Chief Medical Officer reported several stock transactions in early December 2025. On 12/01/2025, the insider sold 2,559 shares of common stock at $102.96 per share and had 100,327 shares beneficially owned afterward. That same day, 17,093 shares were withheld by the company at $102.04 per share to cover tax obligations tied to previously reported restricted stock units and performance shares.
On 12/02/2025, the insider sold an additional 20,105 shares at $102.51 per share, leaving 63,129 shares beneficially owned. According to the explanation, this total includes shares issuable under restricted stock units and earned performance shares that have not yet vested.
Incyte Corporation (INCY) reported insider stock transactions by its Principal Accounting Officer on a Form 4. The officer sold 169 shares of common stock on 11/21/2025 at $102 per share and 600 shares on 11/24/2025 at $103 per share. After these sales, the officer directly owned 23,573 shares of Incyte common stock.
The filing also notes that, including a July 15, 2025 grant, the officer holds an aggregate of 15,166 shares of common stock issuable from previously reported restricted stock units that have not yet vested. These transactions reflect personal trading activity by a company officer and ongoing equity-based compensation.